Which has better valuation and earnings, AXGN or CBLL?

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 9.20 -$15.70M -$0.64 N/A CeriBell $89.06M 8.03 -$53.41M -$1.63 N/A

Is AXGN or CBLL more profitable?

AxoGen has a net margin of -13.21% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -9.63% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% CeriBell -63.51% -38.19% -30.92%

CeriBell (CBLL) Competitors

$18.84 -0.30 (-1.54%)

As of 10:32 AM Eastern

Compare

CBLL vs. TMDX, ESTA, LMAT, AXGN, and BFLY

Should you buy CeriBell stock or one of its competitors? MarketBeat compares CeriBell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CeriBell include TransMedics Group (TMDX), Establishment Labs (ESTA), LeMaitre Vascular (LMAT), AxoGen (AXGN), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.

How does CeriBell compare to TransMedics Group?

CeriBell (NASDAQ:CBLL) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

CeriBell has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	8.03	-$53.41M	-$1.63	N/A
TransMedics Group	$605.49M	4.26	$190.29M	$4.40	16.98

In the previous week, TransMedics Group had 3 more articles in the media than CeriBell. MarketBeat recorded 4 mentions for TransMedics Group and 1 mentions for CeriBell. TransMedics Group's average media sentiment score of 1.62 beat CeriBell's score of 0.72 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Overall Sentiment
CeriBell	Positive
TransMedics Group	Very Positive

99.7% of TransMedics Group shares are held by institutional investors. 20.1% of CeriBell shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TransMedics Group has a net margin of 27.04% compared to CeriBell's net margin of -63.51%. TransMedics Group's return on equity of 22.38% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
TransMedics Group	27.04%	22.38%	8.46%

CeriBell currently has a consensus price target of $22.20, suggesting a potential upside of 17.80%. TransMedics Group has a consensus price target of $134.50, suggesting a potential upside of 80.02%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

TransMedics Group beats CeriBell on 13 of the 17 factors compared between the two stocks.

How does CeriBell compare to Establishment Labs?

CeriBell (NASDAQ:CBLL) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Establishment Labs has a net margin of -19.05% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Establishment Labs	-19.05%	-218.77%	-12.31%

In the previous week, Establishment Labs had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for Establishment Labs and 1 mentions for CeriBell. Establishment Labs' average media sentiment score of 1.24 beat CeriBell's score of 0.72 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
CeriBell	Positive
Establishment Labs	Positive

Establishment Labs has higher revenue and earnings than CeriBell. Establishment Labs is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	8.03	-$53.41M	-$1.63	N/A
Establishment Labs	$211.08M	12.77	-$51.06M	-$1.49	N/A

CeriBell presently has a consensus target price of $22.20, indicating a potential upside of 17.80%. Establishment Labs has a consensus target price of $90.43, indicating a potential downside of 1.24%. Given CeriBell's stronger consensus rating and higher possible upside, research analysts clearly believe CeriBell is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

CeriBell has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

72.9% of Establishment Labs shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Establishment Labs beats CeriBell on 11 of the 17 factors compared between the two stocks.

How does CeriBell compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

84.6% of LeMaitre Vascular shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

LeMaitre Vascular has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.32	$57.73M	$2.71	37.58
CeriBell	$89.06M	8.03	-$53.41M	-$1.63	N/A

LeMaitre Vascular presently has a consensus target price of $112.60, suggesting a potential upside of 10.57%. CeriBell has a consensus target price of $22.20, suggesting a potential upside of 17.80%. Given CeriBell's stronger consensus rating and higher possible upside, analysts clearly believe CeriBell is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

LeMaitre Vascular has a net margin of 24.35% compared to CeriBell's net margin of -63.51%. LeMaitre Vascular's return on equity of 15.36% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
CeriBell	-63.51%	-38.19%	-30.92%

LeMaitre Vascular has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

In the previous week, LeMaitre Vascular had 6 more articles in the media than CeriBell. MarketBeat recorded 7 mentions for LeMaitre Vascular and 1 mentions for CeriBell. LeMaitre Vascular's average media sentiment score of 0.76 beat CeriBell's score of 0.72 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Overall Sentiment
LeMaitre Vascular	Positive
CeriBell	Positive

Summary

LeMaitre Vascular beats CeriBell on 11 of the 16 factors compared between the two stocks.

How does CeriBell compare to AxoGen?

AxoGen (NASDAQ:AXGN) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	9.20	-$15.70M	-$0.64	N/A
CeriBell	$89.06M	8.03	-$53.41M	-$1.63	N/A

AxoGen has a net margin of -13.21% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -9.63% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
CeriBell	-63.51%	-38.19%	-30.92%

In the previous week, AxoGen had 4 more articles in the media than CeriBell. MarketBeat recorded 5 mentions for AxoGen and 1 mentions for CeriBell. AxoGen's average media sentiment score of 0.91 beat CeriBell's score of 0.72 indicating that AxoGen is being referred to more favorably in the media.

Company	Overall Sentiment
AxoGen	Positive
CeriBell	Positive

AxoGen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

AxoGen currently has a consensus price target of $46.50, suggesting a potential upside of 19.30%. CeriBell has a consensus price target of $22.20, suggesting a potential upside of 17.80%. Given AxoGen's higher possible upside, equities analysts plainly believe AxoGen is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

AxoGen beats CeriBell on 13 of the 17 factors compared between the two stocks.

How does CeriBell compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

37.9% of Butterfly Network shares are held by institutional investors. 22.0% of Butterfly Network shares are held by company insiders. Comparatively, 20.1% of CeriBell shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CeriBell has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	17.20	-$77.06M	-$0.30	N/A
CeriBell	$89.06M	8.03	-$53.41M	-$1.63	N/A

Butterfly Network currently has a consensus target price of $5.56, suggesting a potential downside of 15.66%. CeriBell has a consensus target price of $22.20, suggesting a potential upside of 17.80%. Given CeriBell's stronger consensus rating and higher possible upside, analysts clearly believe CeriBell is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Butterfly Network has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

In the previous week, Butterfly Network had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for Butterfly Network and 1 mentions for CeriBell. CeriBell's average media sentiment score of 0.72 beat Butterfly Network's score of 0.68 indicating that CeriBell is being referred to more favorably in the news media.

Company	Overall Sentiment
Butterfly Network	Positive
CeriBell	Positive

CeriBell has a net margin of -63.51% compared to Butterfly Network's net margin of -73.63%. Butterfly Network's return on equity of -34.41% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
CeriBell	-63.51%	-38.19%	-30.92%

Summary

Butterfly Network beats CeriBell on 9 of the 17 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$714.98M	$8.76B	$6.91B	$12.20B
Dividend Yield	N/A	2.56%	2.68%	8.87%
P/E Ratio	-11.56	16.06	27.23	23.90
Price / Sales	8.03	6.89	573.53	111.21
Price / Cash	N/A	18.07	49.25	59.89
Price / Book	4.50	3.30	10.85	6.19
Net Income	-$53.41M	$228.19M	$3.59B	$331.84M
7 Day Performance	-3.66%	-2.09%	-2.26%	-2.30%
1 Month Performance	9.06%	-0.27%	1.89%	-1.63%
1 Year Performance	20.65%	-1.34%	23.86%	16.11%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	1.8893 of 5 stars	$18.85 -1.5%	$22.20 +17.8%	+21.1%	$714.98M	$89.06M	N/A	N/A	Analyst Downgrade
TMDX TransMedics Group	4.5736 of 5 stars	$74.32 -1.9%	$134.50 +81.0%	-32.9%	$2.57B	$605.49M	16.89	210	Positive News
ESTA Establishment Labs	1.4799 of 5 stars	$85.53 -2.7%	$89.71 +4.9%	+111.4%	$2.52B	$211.08M	N/A	1,004	Analyst Forecast
LMAT LeMaitre Vascular	3.9398 of 5 stars	$98.96 -1.3%	$112.60 +13.8%	+24.7%	$2.26B	$249.60M	36.54	490	News Coverage
AXGN AxoGen	2.6641 of 5 stars	$39.19 -0.8%	$46.50 +18.7%	+236.5%	$2.08B	$225.21M	N/A	450

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. TMDX, ESTA, LMAT, AXGN, and BFLY

How does CeriBell compare to TransMedics Group?

Summary

How does CeriBell compare to Establishment Labs?

Summary

How does CeriBell compare to LeMaitre Vascular?

Summary

How does CeriBell compare to AxoGen?

Summary

How does CeriBell compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. TMDX, ESTA, LMAT, AXGN, and BFLY

How does CeriBell compare to TransMedics Group?

Which has more risk & volatility, CBLL or TMDX?

Which has preferable valuation and earnings, CBLL or TMDX?

Does the media prefer CBLL or TMDX?

Do institutionals and insiders have more ownership in CBLL or TMDX?

Is CBLL or TMDX more profitable?

Do analysts recommend CBLL or TMDX?

Summary

How does CeriBell compare to Establishment Labs?

Is CBLL or ESTA more profitable?

Does the media prefer CBLL or ESTA?

Which has stronger valuation and earnings, CBLL or ESTA?

Do analysts prefer CBLL or ESTA?

Which has more risk and volatility, CBLL or ESTA?

Do institutionals & insiders believe in CBLL or ESTA?

Summary

How does CeriBell compare to LeMaitre Vascular?

Do institutionals & insiders have more ownership in LMAT or CBLL?

Which has stronger valuation and earnings, LMAT or CBLL?

Do analysts rate LMAT or CBLL?

Is LMAT or CBLL more profitable?

Which has more risk & volatility, LMAT or CBLL?

Does the media prefer LMAT or CBLL?

Summary

How does CeriBell compare to AxoGen?

Which has better valuation and earnings, AXGN or CBLL?

Is AXGN or CBLL more profitable?

Does the media favor AXGN or CBLL?

Which has more volatility & risk, AXGN or CBLL?

Do analysts recommend AXGN or CBLL?

Do insiders & institutionals hold more shares of AXGN or CBLL?

Summary

How does CeriBell compare to Butterfly Network?

Do institutionals & insiders hold more shares of BFLY or CBLL?

Which has better valuation and earnings, BFLY or CBLL?

Do analysts rate BFLY or CBLL?

Which has more risk & volatility, BFLY or CBLL?

Does the media favor BFLY or CBLL?

Is BFLY or CBLL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools